Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash from Restructuring (2017 - 2018)

Cardiff Oncology's Cash from Restructuring history spans 2 years, with the latest figure at $187500.0 for Q2 2018.

  • For Q2 2018, Cash from Restructuring changed N/A year-over-year to $187500.0; the TTM value through Sep 2019 reached $187500.0, down 35.83%, while the annual FY2020 figure was $34000.0, N/A changed from the prior year.
  • Cash from Restructuring for Q2 2018 was $187500.0 at Cardiff Oncology, up from $104700.0 in the prior quarter.
  • Across five years, Cash from Restructuring topped out at $485000.0 in Q1 2017 and bottomed at $104700.0 in Q4 2017.